The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

Gene therapy developer bluebird bio (NASDAQ:BLUE) announced Friday its plans to become a privately held biotech as part of an M&A agreement with private equity firms, Carlyle Group (NASDAQ:CG) and SK ...

Blue Bird Corporation (BLBD) recently announced fiscal Q1 results, beating top and bottom-line expectations. While the ...

A pair of investors will acquire bluebird bio in a deal worth only $29 million upfront after the gene therapy maker ran out ...

Blue Bird Corporation is a compelling investment due to its focus on electric school buses and attractive stock valuation despite recent performance setbacks. Read more here.

KBC Group NV’s holdings in Blue Bird were worth $55,000 as of its most recent SEC filing. A number of other hedge funds have also recently bought and sold shares of BLBD.

Analysts at DA Davidson boosted their FY2025 EPS estimates for Blue Bird in a note issued to investors on Friday, February 7th. DA Davidson analyst M. Shlisky now anticipates that the company will ...

Blue Bird (NASDAQ:BLBD) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...

Analysts have been eager to weigh in on the Consumer Cyclical sector with new ratings on Blue Bird (BLBD – Research Report) and Alibaba (BABA ...

MACON, Ga.--(BUSINESS WIRE)--Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, has appointed John Wyskiel to the position of President and CEO ...